No Data
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $68
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $48
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $50 to $140
sooogod : How does this company have such a small Trade volume?
10baggerbamm OP sooogod : Bill Gates is backing this company. today's volume is extremely light I don't have an answer for it you see it it stands out like a sore thumb today there's just no buyers.. maybe they're waiting for like a $15.70 print 15.50 print I don't know but what I do know is out of nowhere is it reverses